Who
Alessandra Cesano
Director
Company insider
Files Form 4 as: Director, Puma Biotechnology; Director, Zymeworks; Director, Summit Therapeutics; Chief Medical Officer, ESSA Pharma.
In numbers
- Trades disclosed
- 35
- Buys
- 0
- Sells
- 3
- Bought
- $0
- Sold
- $1.3M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 11 Dec 2020
- Last trade
- 14 Sep 2026
- Last filed
- 16 Sep 2026
Companies traded
Activity over time
1 Jun 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Sep 2026filed 16 Sep 2026 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Code M | $147K50,000 at $2.93 | filing |
| 14 Sep 2026filed 16 Sep 2026 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Sold | $567K62,150 at $9.12 | filing |
| 14 Sep 2026filed 16 Sep 2026 | PBYI Puma Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 14 Sep 2026filed 16 Sep 2026 | PBYI Puma Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 14 Sep 2026filed 16 Sep 2026 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Code M | $147K50,000 at $2.93 | filing |
| 14 Sep 2026filed 16 Sep 2026 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Sold | $567K62,150 at $9.12 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,500 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,700 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —11,500 at $0.00 | filing |
| 12 Jan 2026filed 12 Jan 2026 | ZYME Zymeworksoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,700 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 | filing |
| 2 Jan 2026filed 6 Jan 2026 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $28K3,219 at $8.76 | filing |
| 2 Jan 2026filed 6 Jan 2026 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 | filing |
| 2 Jan 2026filed 6 Jan 2026 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $28K3,219 at $8.76 | filing |
| 18 Jul 2025filed 22 Jul 2025 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Sold | $91K27,000 at $3.37 | filing |
| 13 Jun 2025filed 17 Jun 2025 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Sold | $41K12,150 at $3.40 | filing |
| 11 Jun 2025filed 13 Jun 2025 | PBYI Puma BiotechnologyBiotechnology | SEC FORM 4 Code A | —27,000 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 | filing |
News
No headline names them, or the companies they trade most, lately.